# Matchpoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/matchpoint-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.matchpointtx.com
- Total disclosed funding: $72M
- Latest round: Series A (Oct 5, 2022)
- Investors on record: 6

## About

Founded in 2021 and based in Massachusetts, US, Matchpoint Therapeutics, Inc. is a biotech company that focuses on the development of covalent medicines. Andre Turenne, the company's president and CEO, served as President and Chief Executive Officer of Voyager Therapeutics and Senior Vice President and Global Head of Business Development & Licensing at Sanofi. In 2022, it raised USD 30 million in seed funding co-led by new investors Atlas Venture and Access Industries.

The company's key products include covalent drugs and the advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform provides services such as pathogenic protein identification and proprietary libraries of covalent compounds.

## Funding rounds

- Series A, Oct 5, 2022, $42M — Atlas Venture, Alexandria Venture Investments, Access Industries, Sanofi Ventures, Digitalis Ventures, Vertex Ventures HC
- Seed, Nov 1, 2021, $30M — Atlas Venture, Access Industries

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Seed, Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series A